Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Post-treatment Interleukin-6 (IL-6) levels predict outcomes in severe COVID-19 patients receiving tocilizumab. Transient IL-6 increases after treatment indicate prognostic value, aiding clinical decisions.
Area Of Science
- Immunology
- Virology
- Critical Care Medicine
Background
- Baseline Interleukin-6 (IL-6) is not predictive of tocilizumab treatment outcomes in COVID-19.
- Cytokine storm in severe COVID-19 necessitates reliable prognostic biomarkers.
Purpose Of The Study
- To evaluate post-treatment IL-6 levels as a predictive marker for outcomes in COVID-19 patients treated with tocilizumab.
- To identify reliable biomarkers for prognosis in severe COVID-19 patients.
Main Methods
- Retrospective analysis of 60 severe/critical COVID-19 patients treated with tocilizumab.
- Monitoring of IL-6, D-dimer, C-reactive protein (CRP), procalcitonin (PCT), and fibrinogen levels.
- Receiver Operating Characteristic (ROC) curve analysis to assess IL-6 prognostic utility.
Main Results
- Overall survival rate was 80%; advanced age was an independent risk factor.
- Tocilizumab increased IL-6 and D-dimer, while decreasing CRP, PCT, and fibrinogen.
- Post-treatment IL-6 showed strong predictive capability (AUC=0.812) with optimal cut-off at 147.79 pg/mL.
Conclusions
- Transient post-treatment IL-6 elevation followed by gradual decline is observed.
- Post-treatment IL-6 levels are valuable biomarkers for predicting prognosis in tocilizumab-treated COVID-19 patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...